0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Scalp Dysesthesia FREE

Diane Hoss, MD; Samantha Segal, MD
[+] Author Affiliations

From the Department of Dermatology, University of Connecticut Health Center, Farmington.


Arch Dermatol. 1998;134(3):327-330. doi:10.1001/archderm.134.3.327.
Text Size: A A A
Published online

ABSTRACT

Background  Cutaneous dysesthesia syndrome is a disorder characterized by chronic cutaneous symptoms without objective findings. Patients complain of burning, stinging, or itching, which is often triggered or exacerbated by psychological or physical stress. These symptoms may be manifestations of an underlying psychiatric disorder or may represent a type of chronic pain syndrome.

Observations  Eleven women presented with chronic severe pain and/or pruritus of the scalp only without objective physical findings, a condition we term "scalp dysesthesia." Five women described pain, stinging, or burning only; 4 women complained of pain and pruritus; and 2 women reported pruritus only. The patients ranged in age from 36 to 70 years. The duration of symptoms ranged from 9 months to 7 years. Five women had physician-diagnosed psychiatric disorders, including dysthymic disorder, generalized anxiety, and somatization. Seven women reported that stress triggers or exacerbates their symptoms. Eight women experienced improvement or complete resolution of symptoms with treatment with low-dose doxepin hydrochloride or amitriptyline hydrochloride. One patient responded completely to treatment with sertraline and hydroxyzine hydrochloride but then experienced a relapse.

Conclusions  We describe 11 patients with a new syndrome that we term scalp dysesthesia. Of 11 patients, 9 benefited from treatment with low doses of antidepressants.

THE CHRONIC pain syndromes include the burning mouth syndrome (synonyms: glossodynia, stomatodynia, oral dysesthesia, glossopyrosis, and stomatopyrosis), vulvodynia, scrotodynia, and atypical facial pain (synonym, orofacial dysesthesia). Patients with 1 of these syndromes report localized cutaneous or mucosal debilitating pain or burning, sometimes without abnormal physical findings. We describe 11 women with chronic distressing scalp symptoms, a condition we term "scalp dysesthesia."

REPORT OF CASES

The characteristics of the 11 women with scalp dysesthesia are presented in Table 1, Part A, and Table 1, Part B.

Table Graphic Jump LocationCharacteristics of Women With Scalp Dysesthesia*
Table Graphic Jump LocationCharacteristics of Women With Scalp Dysesthesia* (Continued)

COMMENT

In 1981, Cotterill1 described 28 patients with "dermatologic non-disease." These patients reported significant facial, scalp, and genital burning and discomfort or itching often associated with a disturbed body image (body dysmorphic disorder). Koblenzer and Bostrom2 coined the term "chronic cutaneous dysesthesia syndrome" to refer to patients whose primary cutaneous complaint is dysesthesia. Dysesthesia can be defined as "a disagreeable sensation present with ordinary stimuli."3 Chronic cutaneous dysesthesia is a separate clinical entity from body dysmorphic disorder or a circumscribed delusion, such as delusions of parasitosis.2 Examples of chronic cutaneous dysesthesia include the burning mouth syndrome, vulvodynia, scrotodynia, and atypical facial pain.

When confronted with a patient complaining of localized pain, one must consider possible underlying localized organic disease, systemic organic disease, or psychological disease. In the case of burning mouth syndrome, the physician must rule out local disease (geographic tongue, candidiasis, or contact stomatitis), systemic disease (diabetes, xerostomia due to Sjögren syndrome or medication use, or vitamin deficiencies), or psychological disease.4 Similar consideration must be given to women with vulvodynia3 and patients with orofacial dysestheia.5

Cutaneous disease was present in only 1 of our patients. Patient 6 had biopsy-proven prurigo nodularis of the scalp. These lesions were caused by constant picking of a pruritic and burning scalp in a patient with known atopic dermatitis. Her prurigo nodularis lesions, which were present for 5 years, completely disappeared when her scalp symptoms resolved. None of our patients exhibited signs of psoriasis or seborrheic dermatitis that might have caused their symptoms.

We also considered whether alopecia could have caused or contributed to the scalp dysesthesia in our patients. Of our 11 patients, 7 (2 premenopausal and 5 postmenopausal) had mild androgenetic alopecia (AGA). In 1960, Sulzberger et al6 reported that women with "diffuse alopecia" complained of associated scalp symptoms, including "spotty tenderness, tingling, crawling, itching, burning and uncomfortable awareness of the scalp." Mild AGA is common in women. Venning and Dawber7 noted mild AGA in 220 (87%) of 254 premenopausal women seen in a dermatology clinic for reasons other than hair loss. Thus, our patients do not have an increased incidence of AGA compared with the general population. It is unlikely that mild AGA is the sole cause of the scalp symptoms in these 7 women. Even if mild AGA is the cause, control of scalp symptoms can be achieved without changing the clinical finding of AGA.

Patient 1 had documented telogen effluvium on 2 separate occasions. No cause was determined for the telogen effluvium. The results of a complete blood cell count, thyroid function tests, and iron studies were all normal. Treatment of her scalp burning with doxepin hydrochloride resulted in cessation of burning and decreased daily hair loss on both occasions. A recent review of telogen effluvium does not mention scalp burning associated with increased daily hair loss.8

Temporal arteritis and tension headaches are underlying medical conditions with symptoms that may include scalp pain or tightness. Features that militate against a diagnosis of temporal arteritis in our patients are the diffuse distribution of the scalp pain and the presence of normal erythrocyte sedimentation rates in those patients tested. When queried, all patients stated that their pain did not resemble a headache. The 2 women who reported scalp pruritus without pain had negative or normal results of a laboratory workup for pruritus (complete blood cell count, liver function tests, and measurement of levels of blood urea nitrogen, creatinine, glucose, and thyroid stimulating hormone).

A psychiatric cause or overlay has been reported in patients with chronic pain syndromes or cutaneous dysesthesias.1,2,912 In fact, chronic pain has been referred to as a "depressive equivalent."9 Many of the chronic pain syndromes were initially thought to represent a psychiatric disorder only. However, one must be cautious when reviewing data describing a personality profile or a psychiatric disorder associated with any chronic condition, particularly a painful one.3,13 Is a psychiatric disturbance (ie, depression) the cause of chronic pain or does experiencing chronic pain result in symptoms of depression? A subset of chronic pain sufferers probably do have an underlying psychiatric illness causing their symptoms. However, in the experience of Bowers,13 "most of the cutaneous/mucosal pain syndromes are not caused by psychological pathology." Continued research into the chronic pain syndromes now suggests that they may represent a neurologic dysfunction that in some cases is associated with a secondary psychiatric component.

It is interesting that 5 of our patients had 1 or more physician-diagnosed psychiatric disorders. Dysthymic disorder, a mood disturbance characterized by a chronically depressed mood, was present in 2 patients. Prior somatization was present in 3 patients. Generalized anxiety was present in 4 patients. Of these 5 patients, 4 had psychiatric problems that were present prior to the onset of scalp dysesthesia. Of the 11 patients we describe herein, the symptoms in 7 patients intensified with psychological stress.

A common denominator of many chronic pain syndromes is improvement or complete resolution with treatment with low-dose antidepressants.13 Three possible mechanisms have been proposed14,15: first, antidepressant use may relieve depression associated with or caused by chronic pain and thus improve symptoms; second, the tricyclic antidepressants may have analgesic properties; and/or third, depression and pain may share a similar underlying biochemical mechanism.

Several placebo-controlled studies have documented the efficacy of low-dose antidepressants for treating chronic pain. Postherpetic neuralgia responds to treatment with amitriptyline hydrochloride as demonstrated in a double-blind, placebo-controlled, crossover study.16 There was no significant antidepressive effect with the low doses used (median dose, 75 mg). A 1992 placebo-controlled study17 compared the efficacy of desipramine hydrochloride, amitriptyline, and fluoxetine hydrochloride for treating chronic pain in diabetic neuropathy. Desipramine and amitriptyline were equally effective and superior to placebo in both depressed and nondepressed patients with diabetic neuropathy. Fluoxetine had no greater analgesic effect than placebo in nondepressed patients. Patients who were depressed benefited from fluoxetine therapy. In a retrospective review, McKay18 reported that dysesthetic (essential) vulvodynia responds to treatment with low-dose amitriptyline. Gabapentin, a newly released anticonvulsant medication, has been effective in treating chronic pain syndromes (erythromelalgia19 and reflex sympathetic dystrophy20) in uncontrolled studies. In the future, this drug may prove to be a useful adjunctive therapy for managing a variety of chronic pain syndromes, including scalp dysesthesia.

Of the 11 patients, 9 experienced improvement or complete resolution of their scalp symptoms with low-dose antidepressant treatment. Patient 9 (with pruritus only) was not responsive to numerous therapies including several antidepressants. Patient 5 was unavailable for follow-up. Patient 7 responded to therapy for 1 year but then had a relapse. Patients 1, 6, and 8 reported that symptoms recur if use of the medication is stopped. The positive response to therapy supports our belief that scalp dysesthesia represents a chronic pain syndrome or a subset of the cutaneous dysesthesia syndrome.

It might be argued that patients with only scalp pruritus may have a different condition than those complaining of scalp pain. We included those patients with only pruritus for several reasons: first, several patients with pain or burning reported coexisting pruritus or initial transient pruritus; second, there appeared to be a spectrum of complaints ranging from pain only, to pain and pruritus, to pruritus only; and third, the degree of interference with daily life seemed similar in all patients regardless of their specific symptom. The sensations of both pain and itch are carried on the same unmyelinated (slow), afferent, group C nerve fibers. However, patients with only pruritus were less responsive or unresponsive to therapy with low-dose antidepressants.

CONCLUSIONS

We describe 11 women with scalp dysesthesia, a condition that we believe is a type of chronic cutaneous dysesthesia. These women experienced debilitating scalp pain and/or pruritus. We are not certain if our patients have pain secondary to underlying psychiatric conditions, such as anxiety, dysthymic disorder, and somatization, or if these psychiatric problems are unrelated or caused by the scalp dysesthesia. More studies are needed to determine the cause of scalp dysesthesia and define any role psychiatric diseases may play in causing or enhancing the pain experienced by these patients. Further studies should also formally evaluate the efficacy of treating scalp dysesthesia with low-dose antidepressants.

ARTICLE INFORMATION

Accepted for publication August 3, 1997.

We acknowledge Jean Vogel, MD, for performing psychiatric evaluations of 2 of our patients and Peter Lynch, MD, for providing helpful suggestions regarding therapy with low-dose antidepressants.

Reprints: Diane Hoss, MD, University of Connecticut Health Center, Dowling South, Suite 300, MC 6230, 263 Farmington Ave, Farmington, CT 06030.

REFERENCES

Cotterill  JA Dermatological non-disease: a common and potentially fatal disturbance of cutaneous body image. Br J Dermatol. 1981;104611- 619
Link to Article
Koblenzer  CSBostrom  P Chronic cutaneous dysesthesia syndrome: a psychotic phenomenon or a depressive symptom? J Am Acad Dermatol. 1994;30370- 374
Link to Article
McKay  MBernhard  JDed Vulvodynia, scrotodynia, and other chronic dysesthesias of the anogenital region (including pruritus ani). Itch: Mechanisms and Management of Pruritus New York, NY McGraw-Hill Book Co1994;161- 183
Huang  WRothe  MJGrant-Kels  JM The burning mouth syndrome. J Am Acad Dermatol. 1996;3491- 98
Link to Article
Aghabeigi  B The pathophysiology of pain. Br Dent J. 1992;17391- 97
Link to Article
Sulzberger  MBWitten  VHKopf  AW Diffuse alopecia in women. Arch Dermatol. 1960;81108- 112
Venning  VADawber  RPR Patterned androgenic alopecia in women. J Am Acad Dermatol. 1988;181073- 1077
Link to Article
Headington  JT Telogen effluvium: new concepts and review. Arch Dermatol. 1993;129356- 363
Link to Article
Koblenzer  CSMoschella  SLedHurley  HJed Psychocutaneous disease. Dermatology Philadelphia, Pa WB Saunders Co1992;2025- 2041
Lynch  PJ Vulvodynia: a syndrome of unexplained vulvar pain, psychologic disability and sexual dysfunction. J Reprod Med. 1986;31773- 780
Feinmann  CHarris  MCawley  R Psychogenic facial pain: presentation and treatment. Br Med J (Clin Res Ed). 1984;288436- 438
Link to Article
Hampf  GVikkula  JYlipaavalniemi  PAalberg  V Psychiatric disorders in orofacial dysaesthesia. Int J Oral Maxillofac Surg. 1987;16402- 407
Link to Article
Bowers  KE Cutaneous and mucosal pain syndromes. Med Surg Dermatol. 1995;2129- 132
Lee  RSpencer  PSJ Antidepressants and pain: a review of the pharmacological data supporting the use of certain tricyclics in chronic pain. J Int Med Res. 1977;5(suppl 1)146- 156
Feinmann  C Pain relief by antidepressants: possible modes of action. Pain. 1985;231- 8
Link to Article
Watson  CPEvans  RJReed  KMerskey  HGoldsmith  LWarsh  J Amitriptyline versus placebo in postherpetic neuralgia. Neurology. 1982;32671- 673
Link to Article
Max  MBLynch  SAMuir  JShoaf  SESmoller  BDubner  R Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;3261250- 1256
Link to Article
McKay  M Dysesthetic (‘essential') vulvodynia: treatment with amitriptyline. J Reprod Med. 1993;389- 13
McGraw  TKosek  P Erythromelalgia pain managed with gabapentin. Anesthesiology. 1997;86988- 990
Link to Article
Mellick  GAMellick  LB Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil. 1997;7898- 105
Link to Article

Figures

Tables

Table Graphic Jump LocationCharacteristics of Women With Scalp Dysesthesia*
Table Graphic Jump LocationCharacteristics of Women With Scalp Dysesthesia* (Continued)

References

Cotterill  JA Dermatological non-disease: a common and potentially fatal disturbance of cutaneous body image. Br J Dermatol. 1981;104611- 619
Link to Article
Koblenzer  CSBostrom  P Chronic cutaneous dysesthesia syndrome: a psychotic phenomenon or a depressive symptom? J Am Acad Dermatol. 1994;30370- 374
Link to Article
McKay  MBernhard  JDed Vulvodynia, scrotodynia, and other chronic dysesthesias of the anogenital region (including pruritus ani). Itch: Mechanisms and Management of Pruritus New York, NY McGraw-Hill Book Co1994;161- 183
Huang  WRothe  MJGrant-Kels  JM The burning mouth syndrome. J Am Acad Dermatol. 1996;3491- 98
Link to Article
Aghabeigi  B The pathophysiology of pain. Br Dent J. 1992;17391- 97
Link to Article
Sulzberger  MBWitten  VHKopf  AW Diffuse alopecia in women. Arch Dermatol. 1960;81108- 112
Venning  VADawber  RPR Patterned androgenic alopecia in women. J Am Acad Dermatol. 1988;181073- 1077
Link to Article
Headington  JT Telogen effluvium: new concepts and review. Arch Dermatol. 1993;129356- 363
Link to Article
Koblenzer  CSMoschella  SLedHurley  HJed Psychocutaneous disease. Dermatology Philadelphia, Pa WB Saunders Co1992;2025- 2041
Lynch  PJ Vulvodynia: a syndrome of unexplained vulvar pain, psychologic disability and sexual dysfunction. J Reprod Med. 1986;31773- 780
Feinmann  CHarris  MCawley  R Psychogenic facial pain: presentation and treatment. Br Med J (Clin Res Ed). 1984;288436- 438
Link to Article
Hampf  GVikkula  JYlipaavalniemi  PAalberg  V Psychiatric disorders in orofacial dysaesthesia. Int J Oral Maxillofac Surg. 1987;16402- 407
Link to Article
Bowers  KE Cutaneous and mucosal pain syndromes. Med Surg Dermatol. 1995;2129- 132
Lee  RSpencer  PSJ Antidepressants and pain: a review of the pharmacological data supporting the use of certain tricyclics in chronic pain. J Int Med Res. 1977;5(suppl 1)146- 156
Feinmann  C Pain relief by antidepressants: possible modes of action. Pain. 1985;231- 8
Link to Article
Watson  CPEvans  RJReed  KMerskey  HGoldsmith  LWarsh  J Amitriptyline versus placebo in postherpetic neuralgia. Neurology. 1982;32671- 673
Link to Article
Max  MBLynch  SAMuir  JShoaf  SESmoller  BDubner  R Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;3261250- 1256
Link to Article
McKay  M Dysesthetic (‘essential') vulvodynia: treatment with amitriptyline. J Reprod Med. 1993;389- 13
McGraw  TKosek  P Erythromelalgia pain managed with gabapentin. Anesthesiology. 1997;86988- 990
Link to Article
Mellick  GAMellick  LB Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil. 1997;7898- 105
Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 16

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles